Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Radiographic endpoints including response and progression are important for the evaluation of new glioblastoma therapies. The current RANO criteria was developed to overcome many of the challenges identified with previous guidelines for response assessment, however, significant challenges and limitations remain. The current recommendations build on the strengths of the current RANO criteria, while addressing many of these limitations. Modifications to the current RANO criteria include suggestions for volumetric response evaluation, use contrast enhanced T1 subtraction maps to increase lesion conspicuity, removal of qualitative non-enhancing tumor assessment requirements, use of the post-radiation time point as the baseline for newly diagnosed glioblastoma response assessment, and “treatment-agnostic” response assessment rubrics for identifying pseudoprogression, pseudoresponse, and a confirmed durable response in newly diagnosed and recurrent glioblastoma trials.

Electronic supplementary material

The online version of this article (doi:10.1007/s13311-016-0507-6) contains supplementary material, which is available to authorized users.

Related collections

Most cited references 80

Record: found
Abstract: found
Article: not found

Reporting results of cancer treatment.

A Miller, B Hoogstraten, M. Staquet … (1981)

On the initiative of the World Health Organization, two meetings on the Standardization of Reporting Results of Cancer Treatment have been held with representatives and members of several organizations. Recommendations have been developed for standardized approaches to the recording of baseline data relating to the patient, the tumor, laboratory and radiologic data, the reporting of treatment, grading of acute and subacute toxicity, reporting of response, recurrence and disease-free interval, and reporting results of therapy. These recommendations, already endorsed by a number of organizations, are proposed for international acceptance and use to make it possible for investigators to compare validly their results with those of others.

0 comments Cited 502 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Angiogenesis in brain tumours.

Rakesh Jain, Emmanuelle Di Tomaso, Dan G Duda … (2007)

Despite aggressive surgery, radiotherapy and chemotherapy, malignant gliomas remain uniformly fatal. To progress, these tumours stimulate the formation of new blood vessels through processes driven primarily by vascular endothelial growth factor (VEGF). However, the resulting vessels are structurally and functionally abnormal, and contribute to a hostile microenvironment (low oxygen tension and high interstitial fluid pressure) that selects for a more malignant phenotype with increased morbidity and mortality. Emerging preclinical and clinical data indicate that anti-VEGF therapies are potentially effective in glioblastoma--the most frequent primary brain tumour--and can transiently normalize tumour vessels. This creates a window of opportunity for optimally combining chemotherapeutics and radiation.

0 comments Cited 392 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Tracy T Batchelor, A Gregory Sorensen, Emmanuelle Di Tomaso … (2007)

Using MRI techniques, we show here that normalization of tumor vessels in recurrent glioblastoma patients by daily administration of AZD2171-an oral tyrosine kinase inhibitor of VEGF receptors-has rapid onset, is prolonged but reversible, and has the significant clinical benefit of alleviating edema. Reversal of normalization began by 28 days, though some features persisted for as long as four months. Basic FGF, SDF1alpha, and viable circulating endothelial cells (CECs) increased when tumors escaped treatment, and circulating progenitor cells (CPCs) increased when tumors progressed after drug interruption. Our study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor.

0 comments Cited 349 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Benjamin M. Ellingson: +1-310-4817572 , bellingson@mednet.ucla.edu

Journal

Journal ID (nlm-ta): Neurotherapeutics

Journal ID (iso-abbrev): Neurotherapeutics

Title: Neurotherapeutics

Publisher: Springer US (New York )

ISSN (Print): 1933-7213

ISSN (Electronic): 1878-7479

Publication date (Electronic): 20 January 2017

Publication date PMC-release: 20 January 2017

Publication date (Print): April 2017

Volume: 14

Issue: 2

Pages: 307-320

Affiliations

[1 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, , University of California Los Angeles, ; 924 Westwood Blvd., Suite 615, Los Angeles, CA 90024 USA

[2 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, Department of Radiological Sciences, , University of California Los Angeles, ; Los Angeles, CA USA

[3 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, , University of California Los Angeles, ; Los Angeles, CA USA

[4 ]ISNI 000000041936754X, GRID grid.38142.3c, Center for Neuro-Oncology, Dana-Farber/Brigham and Women’s Cancer Center, , Harvard Medical School, ; Boston, MA USA

[5 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, UCLA Neuro-Oncology Program, , University of California Los Angeles, ; Los Angeles, CA USA

[6 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, Department of Neurology, David Geffen School of Medicine, , University of California Los Angeles, ; Los Angeles, CA USA

Article

Publisher ID: 507

DOI: 10.1007/s13311-016-0507-6

PMC ID: 5398984

PubMed ID: 28108885

SO-VID: ba099d6d-b9ed-42ce-9763-2e66d8e1a4df

License:

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.